British biotech Allergy Therapeutics reports positive early-stage results for its house dust mite immunotherapy.

It’s been a good month for Allergy Therapeutics, which also reported positive Phase II results for its grass pollen allergy vaccine trial last week. It seems to be doing well, with a number of products targeting common allergies in late stage clinical trials.

The company’s observational dust mite immunotherapy study took place across Spain. The 141 participants showed a 43% reduction in a combination of allergy symptoms and need for anti-allergy medication after one year of therapy. There was also a notable reduction in asthma symptoms after immunotherapy treatment — 16.7% after one year vs 50.9% on day one — in a subgroup of people with the condition who took part in the trial.

The modified house-dust mite product used in this study is sold through a patient program in Spain, and is the precursor to the trial vaccine being developed by the company, which is currently in Phase I trials.

It remains to be seen if Allergy Therapeutics can continue with its good fortune in what can be a difficult market to crack, with recent late stage failures from UK-based Circassia Pharmaceuticals, as well as French DBV Technologies.

Previous post

Clinical Trials in Alzheimer's Disease Are Failing: What Can Be Done?

Next post

This Immunotherapy Could Be The First to Treat Milk Allergy in Children

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.